Valuation: United Therapeutics Corporation

Market Cap 23.13B 20.25B 18.69B 17.43B 32.85B 2,187B 33.43B 224B 87.03B 1,079B 86.9B 84.96B 3,760B P/E 2026 *
20.1x
P/E 2027 * 17.2x
Enterprise Value 20.48B 17.93B 16.55B 15.44B 29.09B 1,937B 29.61B 199B 77.08B 956B 76.96B 75.24B 3,330B EV / Sales 2026 *
6.31x
EV / Sales 2027 * 5.2x
Free-Float
53.71%
Yield 2026 *
-
Yield 2027 * -
1 day-0.39%
1 week-0.19%
Current month-2.43%
1 month-0.25%
3 months-7.66%
6 months+9.49%
Current year+11.50%
1 week 535.44
Extreme 535.44
555.32
1 month 532.59
Extreme 532.59
560.97
Current year 455.63
Extreme 455.63
609.35
1 year 272.12
Extreme 272.12
609.35
3 years 208.62
Extreme 208.6249
609.35
5 years 158.38
Extreme 158.38
609.35
10 years 74.31
Extreme 74.31
609.35
Manager TitleAgeSince
Chief Executive Officer 71 1996-06-25
President 54 2016-06-25
Director of Finance/CFO 58 2015-03-12
Director TitleAgeSince
Director/Board Member 78 2001-12-31
Chairman 71 1996-06-25
Director/Board Member 92 2001-12-31
Date Insider Type Main position Quantity % Market Cap.
06-24Fiscal year

Chief Executive Officer

28,500 0.0671%
06-23Fiscal year

Chief Executive Officer

28,500 0.0671%
06-22Fiscal year

Chief Executive Officer

28,500 0.0671%
Change 5-day change 1-year change 3-year change Capi.($)
-0.44%-0.19%+89.07%+146.11% 23.13B
-1.56%+9.59%+55.64%+158.71% 1,097B
-0.91%+7.36%+68.04%+55.07% 622B
-0.93%+7.64%+36.13%+87.55% 449B
-1.62%+6.34%+29.51%+24.01% 334B
-1.38%+3.75%+39.33%+25.04% 294B
+0.30%+2.56%+31.62%+40.64% 286B
-0.10%+2.23%-28.43%-42.77% 213B
+0.21%+4.08%+29.35%+62.67% 195B
-0.23%+0.91%+13.82%+63.73% 157B
Average -0.59%+6.23%+36.41%+62.08% 366.99B
Weighted average by Cap. -0.91%+8.67%+41.95%+79.33%

Financials

2026 *2027 *
Net sales 3.25B 2.84B 2.62B 2.45B 4.61B 307B 4.69B 31.47B 12.22B 152B 12.2B 11.93B 528B 3.7B 3.24B 2.99B 2.79B 5.26B 350B 5.35B 35.9B 13.94B 173B 13.92B 13.61B 602B
Net income 1.26B 1.1B 1.02B 951M 1.79B 119B 1.82B 12.23B 4.75B 58.89B 4.74B 4.64B 205B 1.48B 1.3B 1.2B 1.12B 2.1B 140B 2.14B 14.35B 5.57B 69.09B 5.56B 5.44B 241B
Net Debt -2.65B -2.32B -2.14B -1.99B -3.76B -250B -3.82B -25.64B -9.96B -123B -9.94B -9.72B -430B -3.86B -3.38B -3.12B -2.91B -5.49B -365B -5.59B -37.45B -14.54B -180B -14.52B -14.19B -628B
Logo United Therapeutics Corporation
United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.
Employees
1,400
Date Price Change Volume
26-06-30 US$543.52 -0.26% 148,498
26-06-29 US$544.92 +0.42% 420,258
26-06-26 US$542.66 -0.13% 1,022,244
26-06-25 US$543.39 -1.18% 285,355
26-06-24 US$549.90 +1.02% 377,592
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
544.92USD
Average target price
665.23USD
Spread / Average Target
+22.08%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. UTHR Stock